Aktis Oncology, Inc.
NASDAQ Global SelectTotal Valuation
Aktis Oncology, Inc. carries a market capitalization of 1.05B, placing it among publicly traded companies globally. Its enterprise value stands at 1.28B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.05B |
| Enterprise Value | 1.28B |
Share Statistics
Aktis Oncology, Inc. currently has 55.32M shares outstanding.
| Shares Outstanding | 55.32M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 166.51, and the price-to-book ratio stands at 3.68.
| PE Ratio | N/A |
| PS Ratio | 166.51 |
| PB Ratio | 3.68 |
| P/TBV Ratio | 3.68 |
| P/FCF Ratio | -25.37 |
| P/OCF Ratio | -22.25 |
Enterprise Valuation
| EV / Sales | 126.92 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Aktis Oncology, Inc. maintains a current ratio of 16.33, meaning it holds 16.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 16.33 |
| Quick Ratio | 16.10 |
| Debt / Equity | 2.32 |
| Debt / EBITDA | -0.13 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -30.17 |
| Return on Assets (ROA) | -26.23 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Aktis Oncology, Inc.'s stock has declined approximately -12.36607% over the past 52 weeks. The 50-day moving average sits at 24.03, while the 200-day moving average is 21.58.
| Beta (5Y) | N/A |
| 52-Week Price Change | -12.36607% |
| 50-Day Moving Average | 24.03 |
| 200-Day Moving Average | 21.58 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Aktis Oncology, Inc. generated 10.06M in revenue and converted that into -73.14M in net income, yielding earnings per share of -1.41. EBITDA reached -84.36M, while operating income came in at -87.18M.
| Revenue | 10.06M |
| Gross Profit | N/A |
| Operating Income | -87.18M |
| Pretax Income | -73.14M |
| Net Income | -73.14M |
| EBITDA | -84.36M |
| EBIT | -87.18M |
| Earnings Per Share (EPS) | -1.41 |
Balance Sheet
Aktis Oncology, Inc. holds 517.32M in cash and equivalents against 11.24M in total debt, resulting in a net debt position of -82.49M. Total book value stands at 484.84M, with working capital of 492.41M providing operational flexibility.
| Cash & Cash Equivalents | 517.32M |
| Total Debt | 11.24M |
| Net Debt | -82.49M |
| Equity (Book Value) | 484.84M |
| Book Value Per Share | 8.76 |
| Working Capital | 492.41M |
Cash Flow
Aktis Oncology, Inc. produced -75.29M in operating cash flow over the past twelve months. After subtracting -9.27M in capital expenditures, free cash flow totaled -84.57M - equivalent to -1.63 per share.
| Operating Cash Flow | -75.29M |
| Capital Expenditures | -9.27M |
| Free Cash Flow | -84.57M |
| FCF Per Share | -1.63 |
Margins
Aktis Oncology, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -866.63 and net profit margin of -727.04 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -866.63 |
| Pretax Margin | -727.04 |
| Profit Margin | -727.04 |
| EBITDA Margin | -838.56 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -18.90 |
| FCF Yield | -3.94 |
Scores
Aktis Oncology, Inc. posts an Altman Z-Score of 14.77, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 14.77 |